Identifying drug resistance in multiple myeloma to improve treatment options
Official title: Characterize Drug Resistance in Multiple Myeloma
Funded at Central Arkansas Veterans Hlthcare Sys · NIH-10925595 · Data updated 2026-11-12
This study is looking for special markers in tough multiple myeloma cells that don't respond to treatment, so we can create better therapies to help patients avoid relapse and improve their chances of recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Central Arkansas Veterans Hlthcare Sys NIH-funded |
| Lab location | 1 site (North Little Rock, United States) |
| Project start | October 1, 2024 |
| Project end | September 30, 2028 |
| Funding year | 2025 |
| NIH project number | 1I01BX006235-01A1 |
| Project ID | NIH-10925595 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with multiple myeloma, particularly those who have experienced treatment resistance.
✕Less likely to help
Patients with early-stage multiple myeloma who have not yet undergone treatment may not benefit from this research.
What this research studies
This research aims to identify specific biomarkers associated with drug-resistant multiple myeloma (MM) cells. By analyzing the molecular signatures and regulatory elements of these cells, the researchers hope to develop new therapies that can effectively target and eliminate drug-resistant cells, thereby preventing relapse. The study utilizes advanced techniques such as single-cell multi-omics profiling and CAR-T cell therapy to enhance treatment efficacy. Patients may benefit from innovative treatment strategies tailored to their unique cancer profiles.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies that prevent relapse in multiple myeloma patients.
How similar studies have gone: Previous research has shown promise in using CAR-T cell therapy for treating multiple myeloma, indicating potential success for this approach.
Where this research is happening
-
Central Arkansas Veterans Hlthcare Sys
North Little Rock, United States Active
Researchers
- Principal investigator: Zhan, Fenghuang — Central Arkansas Veterans Hlthcare Sys
- Study coordinator: Zhan, Fenghuang
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.